Adjuvant S-1 chemotherapy after curative resection of gastric cancer in Chinese patients: assessment of treatment tolerability and associated risk factors
Publication in refereed journal

香港中文大學研究人員
替代計量分析
.

其它資訊
摘要INTRODUCTION:

The use of adjuvant chemotherapy with S-1 (tegafur, gimeracil, and oteracil potassium) has been shown to improve the outcome of patients with gastric cancer. There are limited data on the tolerability of S-1 in Chinese patients. In this multicentre retrospective study, we assessed the toxicity profile in local patients.

METHODS:

Patients with stage II-IIIC gastric adenocarcinoma who had undergone curative resection and who had received S-1 adjuvant chemotherapy were included in the study. Patient demographics, tumour characteristics, chemotherapy records, as well as biochemical, haematological, and other toxicity profiles were extracted from medical charts. Potential factors associated with grade 2-4 toxicities were identified.

RESULTS:

Adjuvant S-1 was administered to 30 patients. Overall, 19 (63%) patients completed eight cycles. The most common grade 3-4 adverse events included neutropaenia (10%), anaemia (6.7%), septic episode (16.7%), diarrhoea (6.7%), hyperbilirubinaemia (6.7%), and syncope (6.7%). Dose reductions were made in 22 (73.3%) patients and 12 (40.0%) patients had dose delays. Univariate analyses showed that patients who underwent total gastrectomy were more likely to experience adverse haematological events (P=0.034). Patients with nodal involvement were more likely to report adverse non-haematological events (P=0.031). Patients with a history of regular alcohol intake were more likely to have earlier treatment withdrawal (P=0.044). Lower body weight (P=0.007) and lower body surface area (P=0.017) were associated with dose interruptions.

CONCLUSIONS:

The tolerability of adjuvant S-1 in our patient population was similar to that in other Asian patient populations. The awareness of S-1-related toxicities and increasing knowledge of potential associated factors may enable optimisation of S-1 therapy.
著者Yeo W, Lam KO, Law AL, Lee CC, Chiang CL, Au KH, Mo FK, So TH, Lam KC, Ng WT, Li L
期刊名稱Hong Kong Medical Journal
詳細描述Epub 2016 Dec 14
出版年份2017
月份2
卷號23
期次1
出版社Hong Kong : Hong Kong Academy of Medicine Press
出版地China
頁次54 - 62
國際標準期刊號1024-2708
電子國際標準期刊號2226-8707
語言英式英語
關鍵詞Drug combinations, Risk factors, Stomach neoplasms/drug therapy, Treatment outcome

上次更新時間 2021-26-01 於 23:20